+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global BCR ABL Tyrosine Kinase Inhibitor Drug Market, Drug Price, Sales & Clinical Trials Insight 2029

  • PDF Icon

    Report

  • 240 Pages
  • June 2023
  • Region: Global
  • Kuick Research
  • ID: 5835601
Description Jump to:

Report Highlights:

  • Global BCR ABL Inhibitor Drug Market Opportunity: > USD 8 Billion
  • BCR ABL Inhibitor Drug Market Global and Regional Analysis
  • Approved Drugs Sales Insight (2019 - Q1’2023)
  • Approved Drugs Dosage, Patent, and Price Insight
  • BCR ABL Inhibitors Drugs Clinical Trials By Company, Indication, and Phase:  > 20 Drugs
  • Clinical Insight On Approved BCR ABL Inhibitors Drugs: 10 Drugs
  • Competitive Landscape: insight into 27 Companies

BCR ABL inhibitors have transformed the treatment landscape for patients of chronic myeloid leukemia (CML). These inhibitors work by blocking the activity of the constitutively active BCR ABL fusion protein, which is encoded by the unnatural BCR-ABL gene, itself a product of chromosomal translocation. By directly acting on the protein held responsible for the development of this form of leukemia, researchers and drug developers have achieved great success in the past few years and so have these patients, who were mainly treated through chemotherapy, an approach coming with several adverse effects. At present, there are seven BCR-ABL inhibitors that have been approved for commercialization across the world along with some more that have approvals in specific regions. The market for BCR-ABL inhibitors is driven by the increasing cases of myeloid leukemia and is expected to see high growth in the coming years.

Imatinib was the first BCR ABL inhibitor to be approved for the treatment of chronic myeloid leukemia, and as a first-generation inhibitor, its clinical and commercial success led to the development of more efficient BCR ABL inhibitors. It was commercialized across the world by the names of Gleevec and Glivec. However, following the expiration of its patent, Gleevec and Glivec have faced severe competition from generic versions of Imatinib, which have been challenging their share in the global market and have managed to chip off their sales. However, with the presence of other BCR ABL inhibitors in the market and more in the pipelines, sales of BCR ABL inhibitors are expected to dominate over generic drugs’ sales.

Scemblix (Asciminib) was the most recent BCR ABL inhibitor to be approved for sale in the market for the treatment of BCR ABL mutation-positive chronic myeloid leukemia and patients having the T315I mutation. It is a third-generation BCR ABL inhibitor, which was granted accelerated approval in the US in 2021, and successfully turned into full approval in 2022. Scemblix and other new-generation BCR ABL inhibitors have been designed to specifically treat patients who have developed resistance to treatment with Imatinib. Along with this, they have also been designed to counter the T315I mutation, which is notable for helping develop resistance to tyrosine kinase inhibitors.

In 2022, the market for BCR ABL inhibitors was valued at around US$ 6 Billion, with Sprycel making up 27% of this. Developed by Bristol-Myers Squibb, Sprycel has been approved for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phases, adults with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who have developed resistance to or intolerance to prior therapies, such as Imatinib. In addition, Sprycel can also be used for the treatment of adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL), who have developed resistance to or intolerance to prior therapy, including Imatinib. Its approval as a first-line therapy has played a crucial role in its increasing sales, which have been rising every year.

While the market is majorly dominated by certain pharmaceutical companies such as Novartis, Pfizer, Bristol-Myers Squibb, and Bayer, smaller companies have been venturing into the market too with their novel BCR ABL inhibitors, which are aimed to provide better therapeutic effects with limited adverse effects compared to these drugs having an already established market. For instance, Fusion Pharma, a Russia-based company, has been conducting clinical trials for its candidate PF-114 for the treatment of patients with resistance forms of chronic myeloid leukemia, including those having T315I mutation. While phase I/II trials for PF-114 are underway, the company has planned phase 3 trials for using the drug as a 1st, 2nd, and 3rd line therapy for chronic myeloid leukemia patients bearing the T315I mutation. Often referred to as a fourth-generation inhibitor PF-114 might have the key to treating patients resistant to other BCR ABL inhibitors.

Conclusively, the research and development activities for BCR ABL inhibitors have been gaining speed in recent years as more of these are getting approved in the past few years. Moreover, with the increasing focus of the pharmaceutical industry of addressing the needs of rare cancers, more companies are expected to delve into the development of novel BCR ABL inhibitors having unique mechanisms of action. Additionally, the patent expirations of the approved drugs have allowed the entry of generic versions in the market, which have helped increase the accessibility of patients to these drugs, therefore boosting the generic drugs market as well. Several favorable parameters are currently fanning market growth as a result of which, the BCR ABL inhibitors market is anticipated to gain more attention and investments in the coming years.

Table of Contents

1. Introduction to BCR-ABL Inhibitors
1.1 Overview
1.2 Mechanism of Action of BCR-ABL Inhibitors
1.3 Role of BCR-ABL Inhibitor in Cancer

2. Global BCR-ABL Inhibitor Drug Market Insight
2.1 Current Market Scenario
2.2 Future Market Opportunity

3. BCR-ABL Inhibitor Drug Market Regional Analysis
3.1 US
3.2 Europe
3.3 Japan
3.4 Rest of World

4. BCR-ABL Inhibitor Drug Market by Product
4.1 First Generation BCR-ABL Inhibitor
4.2 Second Generation BCR-ABL Inhibitor
4.3 Third Generation BCR-ABL Inhibitor

5. Imatinib - 1st Generation BCR-ABL Inhibitor
5.1 Overview
5.2 Patent & Exclusivity
5.3 Pricing & Dosage Analysis
5.3.1 Branded
5.3.2 Generic
5.4 Sales Analysis

6. Dasatinib - 2nd Generation BCR-ABL Inhibitor
6.1 Overview
6.2 Patent & Exclusivity
6.3 Pricing & Dosage Analysis
6.3.1 Branded
6.3.2 Generic
6.4 Sales Analysis

7. Nilotinib - 2nd Generation BCR-ABL Inhibitor
7.1 Overview
7.2 Patent & Exclusivity
7.3 Price & Dosage Analysis
7.4 Sales Analysis

8. Bosutinib - 2nd Generation BCR-ABL Inhibitor
8.1 Overview
8.2 Patent & Exclusivity
8.3 Pricing & Dosage Analysis
8.4 Sales Analysis

9. Ponatinib - 3rd Generation BCR-ABL Inhibitor
9.1 Overview
9.2 Patent & Exclusivity
9.3 Pricing & Dosage Analysis
9.4 Sales Analysis

10. Asciminib - 3rd Generation BCR-ABL Inhibitor
10.1 Overview
10.2 Patent & Exclusivity
10.3 Pricing & Dosage Analysis
10.4 Sales Analysis

11. Olverembatinib - 3rd Generation BCR-ABL Inhibitor
11.1 Overview & Patent Analysis
11.2 Sales Analysis

12. BCR-ABL Inhibitor Market Clinical Trial Insights
12.1 By Indication
12.2 By Company
12.3 By Country
12.4 By Patient Segment
12.5 By Phase

13. Global Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Trials By Company, Indication & Phase
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-II/III
13.6 Phase-III
13.7 Preregistration
13.8 Registered

14. Marketed Bcr Abl Tyrosine Kinase Inhibitors Drugs Clinical Insight Company & Indication
15. BCR-ABL Inhibitors Market Dynamics
15.1 Market Favorable Parameters
15.2 Market Challenges

16. Competitive Landscape
16.1 1St Biotherapeutics
16.2 Aerovate Therapeutics
16.3 Ascentage Pharma
16.4 AtlasMedx
16.5 Bayer HealthCare
16.6 BenevolentAI
16.7 CSPC Ouyi Pharmaceutical
16.8 Deciphera Pharmaceuticals
16.9 Exvastat
16.10 Fusion Pharma
16.11 Georgetown University
16.12 Guangzhou Institutes of Biomedicine and Health
16.13 Il-Yang
16.14 Inhibikase Therapeutics
16.15 Jiangsu Hansoh Pharmaceutical
16.16 Novartis
16.17 Novartis Pharmaceuticals Corporation
16.18 Pfizer
16.19 Pharm-Sintez
16.20 Shenzhen TargetRx
16.21 Sun Pharma Advanced Research Company
16.22 Takeda
16.23 Terns Pharmaceuticals
16.24 Theseus Pharmaceuticals
16.25 Vectura
16.26 Xspray Pharma
16.27 YD Global Life Science

List of Figures
Figure 1-1: Therapeutic Options for Management of CML
Figure 1-2: Evolution of BCR-ABL Inhibitors Development
Figure 1-3: Imatinib - Mechanism of Action in CML
Figure 1-4: Pathways Regulated by BCR-ABL in Cancer
Figure 2-1: Global - Estimated Leukemia Incidences and Death, 2020 and 2025
Figure 2-2: BCR-ABL Inhibitor - Drugs Sales (US$ Million), Q1’2023
Figure 2-3: BCR-ABL Inhibitor - Drugs Sales (%), Q1’2023
Figure 2-4: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2022
Figure 2-5: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2021
Figure 2-6: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2020
Figure 2-7: BCR-ABL Inhibitor - Drugs Sales (US$ Million), 2019
Figure 2-8: Global - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion),   2023-2029
Figure 3-1: US - Leukemia Incidences and Death, 2020 and 2025
Figure 3-2: US vs. ROW - BCR-ABL Inhibitor Drugs Market (US$ Billion), 2022
Figure 3-3: US vs. ROW - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 3-4: US - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Billion), 2023 - 2029
Figure 3-5: Europe - Leukemia Incidences and Death, 2020 and 2025
Figure 3-6: Europe - BCR-ABL Inhibitors Drugs  Market Opportunity (US$ Million), 2023 - 2029
Figure 3-7: Japan - Leukemia Incidences and Death, 2020 and 2025
Figure 3-8: Japan - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2022 - 2028
Figure 3-9: China - Leukemia Incidences and Death, 2020 and 2025
Figure 3-10: India - Leukemia Incidences and Death, 2020 and 2025
Figure 3-11: China - BCR-ABL Inhibitors Drugs Market Opportunity (US$ Million), 2023 - 2029
Figure 4-1: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-2: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-3: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-4: First Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-5: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-6: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-7: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), Q1’2023
Figure 4-8: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), Q1’2023
Figure 4-9: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-10: Second Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 4-11: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (US$ Million), 2022
Figure 4-12: Second Generation BCR-ABL Inhibitor Drugs Market by Drug Type (%), 2022
Figure 4-13: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), Q1’2023
Figure 4-14: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), Q1’2023
Figure 4-15: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (US$ Million), 2022
Figure 4-16: Third Generation vs. Others - BCR-ABL Inhibitor Drugs Market (%), 2022
Figure 5-1: US - Imatinib FDA Orphan Drug Designation by Indication
Figure 5-2: Imatinib - Approval Year by Region
Figure 5-3: US - Gleevec FDA Approval History by Indication
Figure 5-4: US - Gleevec Patent Approval and Expiration Year
Figure 5-5: Imatinib - Ist Generic Approval by Region
Figure 5-6: US - Cost of Supply of 90 Tablets and Per Unit Cost of Gleevec 100mg (US$), April’2023
Figure 5-7: US - Cost of Supply of 30 Tablets and Per Unit Cost of Gleevec 400mg (US$), April’2023
Figure 5-8: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Glivec 100mg (GBP/US$), April’2023
Figure 5-9: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Glivec 400mg(GBP/US$), April’2023
Figure 5-10: US - Cost of Supply of 30 Tablets and Per Unit Cost of Imatinib 100mg(US$), April’2023
Figure 5-11: US - Cost of Supply of 90 Tablets and Per Unit Cost of Imatinib 100mg (US$), April’2023
Figure 5-12: US - Cost of Supply of 30 Tablets and Per Unit Cost of Imatinib 400mg (US$), April’2023
Figure 5-13: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Imatinib 100mg (GBP/US$), April’2023
Figure 5-14: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Glivec 400mg (GBP/US$), April’2023
Figure 5-15: Imatinib - Recommended Initial Dose in Adult by Therapeutic Condition (mg/day)
Figure 5-16: Global - Gleevec/Glivec Annual Sales (US$ Million), 2019-2023
Figure 5-17: US - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-18: ROW - Gleevec/Glivec Yearly Sales (US$ Million), 2019-2023
Figure 5-19: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), Q1’2023
Figure 5-20: Gleevec/Glivec - Annual Sales by Region (%), Q1’2023
Figure 5-21: Global - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-22: Regional - Gleevec/Glivec Quarterly Sales (US$ Million), 2022
Figure 5-23: Gleevec/Glivec - Annual Sales by Region (%), 2022
Figure 6-1: US - Sprycel Orphan Drug Designation Approval and Exclusivity for CML
Figure 6-2: US - Sprycel Orphan Drug Designation Approval and Exclusivity for Ph+ ALL
Figure 6-3: US - Sprycel Orphan Drug Designation and FDA Approval Year
Figure 6-4: Sprycel - Approval Year by Region
Figure 6-5: US - Sprycel Approval Year by Indication
Figure 6-6: US - Sprycel Patent Approval and Expiration Year
Figure 6-7: Japan - Sprycel Approval and Patent Exclusivity Year
Figure 6-8: Europe - Branded and 1st Generic Approval Year
Figure 6-9: US - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 20mg (US$), April’2023
Figure 6-10: US - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 50mg and 70mg (US$), April’2023
Figure 6-11: US - Cost of Supply of 30 Tablets and Per Unit Cost of Sprycel 80mg,100mg and 140mg (US$), April’2023
Figure 6-12: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Sprycel 20mg (GBP/US$), April’2023
Figure 6-13: UK - Cost of Supply of 60/30 Tablets and Per Unit Cost of Sprycel 50mg, 80mg, 100mg and 140mg (GBP/US$), April’2023
Figure 6-14: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Dasatinib 20mg (GBP/US$), April’2023
Figure 6-15: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Dasatinib 50mg, 80mg, 100mg and 140mg (GBP/US$), April’2023
Figure 6-16: Dasatinib - Initial Recommended Dose by Indication for Adults (mg/day)
Figure 6-17: Dasatinib - Initial Recommended Dose by Indication for Pediatric Patients by Weight (mg/day)
Figure 6-18: Global - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-19: Regional - Sprycel Annual Sales (US$ Million), Q1’2023
Figure 6-20: Regional - Sprycel Annual Sales (%), Q1’2023
Figure 6-21: Regional - Sprycel Annual Sales (US$ Million), 2022
Figure 6-22: Regional - Sprycel Annual Sales (%), 2022
Figure 6-23: Global - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-24: US - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-25: ROW - Sprycel Quarterly Sales (US$ Million), 2022
Figure 6-26: US - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 6-27: ROW - Sprycel Annual Sales (US$ Million), 2019-2023
Figure 7-1: US - Tasigna Orphan Drug Designation Approval and Exclusivity for CML
Figure 7-2: Tasigna - Approval Year by Region
Figure 7-3: US - Tasigna Orphan Drug Designation and Approval Year
Figure 7-4: Europe - Tasigna Orphan Drug Designation and Approval Year
Figure 7-5: US - Tasigna Approval History by Indication
Figure 7-6: US - Tasigna Patent Approval and Expiration Year
Figure 7-7: Canada - Tasigna Patent Approval and Expiration Year
Figure 7-8: US - Tasigna FDA Approval and Patent Exclusivity Year
Figure 7-9: Europe - Tasigna EMA Approval and Patent Exclusivity Year
Figure 7-10: US - Cost of Supply of 120 Capsules and Per Unit Cost of Tasigna 50mg(US$), April’2023
Figure 7-11: US - Cost of Supply of 28 Capsules and Per Unit Cost of Tasigna 150mg and 200mg (US$), April’2023
Figure 7-12: US - Cost of Supply of 112 Capsules and Per Unit Cost of Tasigna 1500mg and 200mg (US$), April’2023
Figure 7-13: UK - Cost of Supply of 120 Capsules and Per Unit Cost of Tasigna 50mg(GBP/US$), April’2023
Figure 7-14: UK - Cost of Supply of 112 Capsules and Per Unit Cost of Tasigna 150mg and 200mg (GBP/US$), April’2023
Figure 7-15: Nilotinib - Initial Recommended Dose by Indication (mg/day)
Figure 7-16: Nilotinib - Minimum and Maximum Recommended Dose in Pediatric CML (mg/day)
Figure 7-17: Global - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-18: Tasigna - Annual Sales by Region (US$ Million), 2022
Figure 7-19: Tasigna - Annual Sales by Region (%), 2022
Figure 7-20: Global - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-21: US - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-22: ROW - Tasigna Quarterly Sales (US$ Million), 2022
Figure 7-23: US - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 7-24: ROW - Tasigna Annual Sales (US$ Million), 2019-2023
Figure 8-1: US - Bosulif Orphan Drug Designation Approval and Exclusivity for CML
Figure 8-2: Bosulif - Approval Year by Region
Figure 8-3: US - Bosulif Orphan Drug Designation and Approval Year
Figure 8-4: US - Bosulif Approval by Indication
Figure 8-5: US - Bosulif Patent Approval and Expiration Years
Figure 8-6: Europe - Bosulif EMA Approval and Patent Exclusivity Year
Figure 8-7: US - Cost of Supply of 120 Tablets and Per Unit Cost of Bosulif 100mg (US$), April’2023
Figure 8-8: US - Cost of Supply of 120 Tablets and Per Unit Cost of Bosulif 400mg and 500mg (US$), April’2023
Figure 8-9: UK - Cost of Supply of 28 Tablets and Per Unit Cost of Basulif 100mg (GBP/US$), April’2023
Figure 8-10: UK - Cost of Supply of 28 Tablets and Per Unit Cost of Bosulif 400mg and 500mg (GBP/US$), April’2023
Figure 8-11: Bosulif- Initial Recommended Dose by Indication for Adults (mg/day)
Figure 8-12: Bosulif- Minimum and Maximum Recommended Dose (mg/day)
Figure 8-13: Global - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-14: US - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-15: Europe - Bosulif Annual Sales (US$ Million), 2019-2023
Figure 8-16: Regional - Bosulif Quarterly Sales (US$ Million), Q1’2023
Figure 8-17: Regional - Bosulif Quarterly Sales (%), Q1’2023
Figure 8-18: Bosulif - Annual Sales by Region (US$ Million), 2022
Figure 8-19: Bosulif - Annual Sales by Region (%), 2022
Figure 8-20: Global - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-21: US - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-22: Europe - Bosulif Quarterly Sales (US$ Million), 2022
Figure 8-23: ROW - Bosulif Quarterly Sales (US$ Million), 2022
Figure 9-1: Iclusig - Orphan Drug Designation by Region
Figure 9-2: US - Iclusig Orphan Drug Designation and Approval Year
Figure 9-3: Europe - Iclusig Orphan Drug Designation and Approval Year
Figure 9-4: Iclusig - Approval Year by Region
Figure 9-5: US - Iclusig Approval by Indication
Figure 9-6: US - Iclusig Patent Approval and Expiration Year
Figure 9-7: Europe - Iclusig EMA Approval and Patent Exclusivity Year
Figure 9-8: Japan - Iclusig Approval and Patent Exclusivity Year
Figure 9-9: US - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig Oral Tablet(US$), April’2023
Figure 9-10: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig 15mg(GBP/US$), April’2023
Figure 9-11: UK - Cost of Supply of 30 Tablets and Per Unit Cost of Iclusig 30mg and45mg (GBP/US$), April’2023
Figure 9-12: Ponatinib - Initial and Dose Reductions for CP-CML (mg/day)
Figure 9-13: Ponatinib - Initial and Dose Reductions for Resistant CML and Ph+ ALL (mg/day)
Figure 9-14: Global - Iclusig Annual Sales (US$ Million), 2019-2023
Figure 9-15: Global - Iclusig Quarterly Sales (US$ Million), 2022
Figure 10-1: US - Scemblix Orphan Drug Designation and Approval Year
Figure 10-2: Scemblix - Approval Year by Region
Figure 10-3: US - Scemblix Patent Issue and Expiration Year
Figure 10-4: US - Scemblix FDA Approval and Patent Exclusivity Year
Figure 10-5: US - Cost of Supply of 60 Tablets and Per Unit Cost of Scemblix Oral Tablet (US$), April’2023
Figure 10-6: UK - Cost of Supply of 60 Tablets and Per Unit Cost of Scemblix Oral Tablet (US$), April’2023
Figure 10-7: Scemblix - Initial and Dose Reductions for Ph+ CML-CP, Previously Treated with Two or More TKIs (mg/day)
Figure 10-8: Scemblix - Initial and Dose Reductions for Ph+ CML-CP with the T315I Mutation (mg/day)
Figure 10-9: Global - Scemblix Quarterly Sales (US$ Million), 2022-2023
Figure 10-10: Global - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-11: US - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-12: ROW - Scemblix Quarterly Sales (US$ Million), 2022
Figure 10-13: Scemblix - Annual Sales by Region (%), 2022
Figure 11-1: China - Olverembatinib Priority Review, Breakthrough Therapy Designation and NMPA Approval Year
Figure 11-2: Olverembatinib - Orphan Designation by Region
Figure 11-3: Global - Olverembatinib Half-Yearly Sales (US$ Million), 2022
Figure 12-1: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Indication, 2023
Figure 12-2: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Company, 2023
Figure 12-3: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Country, 2023
Figure 12-4: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Patient Segment, 2023
Figure 12-5: Global - Bcr Abl Inhibitor Drugs in Clinical Trials by Phase, 2023
Figure 15-1: BCR-ABL Inhibitor Market Drivers
Figure 15-2: BCR-ABL Inhibitor Market Challenges

List of Tables
Table 1-1: Frequency of BCR-ABL Gene in Different Phenotypes of Leukemia
Table 15-1: BCR-ABL Inhibitors and Resistance Mechanisms

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 1St Biotherapeutics
  • Aerovate Therapeutics
  • Ascentage Pharma
  • AtlasMedx
  • Bayer HealthCare
  • BenevolentAI
  • CSPC Ouyi Pharmaceutical
  • Deciphera Pharmaceuticals
  • Exvastat
  • Fusion Pharma
  • Georgetown University
  • Guangzhou Institutes of Biomedicine and Health
  • Il-Yang
  • Inhibikase Therapeutics
  • Jiangsu Hansoh Pharmaceutical
  • Novartis
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Pharm-Sintez
  • Shenzhen TargetRx
  • Sun Pharma Advanced Research Company
  • Takeda
  • Terns Pharmaceuticals
  • Theseus Pharmaceuticals
  • Vectura
  • Xspray Pharma
  • YD Global Life Science

Related Topics

Related Reports

Tyrosine Kinase Inhibitors Global Market Report 2024 - Product Image

Tyrosine Kinase Inhibitors Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2024 - Product Image

Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Tyrosine Kinase Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Tyrosine Kinase Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Tyrosine Kinase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Tyrosine Kinase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Forecast 2024-2030 - Product Image

Global Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.